small cell lung cancer, SCLC14%SCLC1programmed death 1, PD-1T4cytotoxic T-lymphocyte-associated antigen 4, CTLA-4SCLCSCLCSCLC strong course=”kwd-title” Keywords: , , Abstract Little cell lung cancer (SCLC) is definitely a poorly differentiated high-grade neuroendocrine tumor, makes up about approximately 14% of most lung cancers. practice of several types of solid tumor. SCLC can be a potential ideal kind of tumor immunotherapy for cigarette exposure and the best mutational load. With this Rabbit polyclonal to ZNF138 record, the writers review the existing state from the immunotherapy in SCLC, to discussing the problems, challenge and application development prospect. strong class=”kwd-title” Keywords: Small cell lung cancer, Immune checkpoint, Immune checkpoint inhibitor small cell lung cancer, SCLC14%SCLCSCLCSCLC1002011IpilimumabipilimumabNivolumabPembrolizumabAtezolizumabAvelumabSCLC 1.?SCLC 1.1. CTLA-4 SCLC[1]SCLCCTLA-4IpilimumabCA184-041 extensive-stage small cell lung 2-Methoxyestradiol kinase inhibitor cancer, ED-SCLCIpilimumabimmune-related progression-free survivalirPFS[2]CA184-156[3]IpilimumabED-SCLCoverall surviva, OSprogression-free survival, PFSIpilimumabTT 1.2. PD-1 PD-1NivolumabSCLC-1/-1programmed death-1/PD-1 ligand 1, PD-1/PD-L1CTLA-4T2015American Society of Clinical Oncology, ASCONivolumabIpilimumabSCLCCheckMate 032[4]SCLC2016 em Lancet Oncol /em [5]SCLCNivolumabNivolumabIpilimumabCheckMate 0322SCLC1[6, 7]2016World Conference on Lung Cancer, WCLC2[8]30%National Comprehensive Cancer Network, NCCN2017NivolumabIpilimumabNivoIpiSCLC[9]SCLC2017ASCO[10]blinded independented central review, BICRobjective response rate, ORR23%2OS26%OS7.8ORR11%2OS14%OS4.1116PD-L1SCLCPD-L11%18%PD-L1ORR21%12%3PFS30%18%3OS64%65%ORR22%11%3-478%45%3-41.8-16.3NivoIpiCheckMate 032SCLCCheckMate 331NivoSCLCSCLCNivoSCLCCheck Mate 451NivoNivo+IpiED-SCLCSCLCNivoIpiSCLCRovalpituzumabED-SCLC/NCT03026166SCLC PD-1PembrolizumabSCLCKEYNOTE-0281b[11]22C31%PD-L1SCLCPembrolizumab147PD-L14224366.7%16/2416.7%16.7%16.7%12.5%12.5%12.5%3/24PembrolizumabORR33.3%PFS1.9OS9.7137.7%PembrolizumabPD-L1SCLCPembroSCLCNCT02963090PembroSCLC2017ASCOpembro4-6ED-SCLCPFS[12]45PFS1.4irPFS4.7OS9.242%Pembro311CALGB 305042.13.7PFSPembroPembroOSCALGB 30504[13]9.0OS6.9OSPembroPFSOSRECISTiRECISTPembroiPFS4.7OSSCLCPembroPD-L1, PD-L1PembroSCLCPembroKEYNOTE-011, REACTIONPembroPlus, MISP-MK3475ED-SCLCPembroSCLCNCT02402920PembroPI3KSCLCNCT02646748PembroSCLC 1.3. PD-L1 2-Methoxyestradiol kinase inhibitor PD-L1AtezolizumabDurvalumabAvelumabSCLCSCLCAtezolizumabPCD4989g[14]AtezolizumabSCLCIaPD-L1PD-L1VENTANA PD-L1 (SP142) IHCtumor cell, TCimmune cell, ICPD-L117SCLC65%3Atezoz111-2231315ORR6%1.124%PFS1.595% CI: 1.2-2.7OS5.995% CI: 4.3-20.1PD-L1immunohistochemistry, IHCPD-L1 mRNAPFSOSPD-L1irPFSOSTTeffAtezolizumabTeffirPFSOSAtezoES-SCLCAtezolizumab AtezolizumabSCLCNCT02748889, IMpower133, NCT03041311Durvalumab2016SCLCDurvalumab/TremelimumabED-SCLCCaspianDurvalumab/TremelimumabSCLCNCT02701400DurvalumabDNAPARPOlaparibSCLC/MEDIOLAAvelumabSCLCSCLC 2.?SCLC SCLCPD-L1SCLCKEYNOTE-028[11]SCLCPD-L11%ORR33.3%PCD4989g[11]PD-L1OSCheckMate 032[5]PD-L1SCLCPD-L1Yu[15]98SCLCSCLCSP142Dake28-8PD-L1mRNAPD-L11% 5%11.6%SP14210.4%Dake28-812.6%Dake28-8PD-L15% 10%0SP1423.0%Dake28-80%Dake28-8PD-L110% 50%2.1SP1423.0%Dake28-81.1%Dake28-8PD-L150%1.1SP1423.0%Dake28-81.1%Dake28-8LD-SCLCPD-L1 mRNA15.5%SCLCPD-L1non-small 2-Methoxyestradiol kinase inhibitor cell lung cancer, 2-Methoxyestradiol kinase inhibitor NSCLCSCLCPD-L1NSCLCSCLCNSCLCSCLC PD-L1[16]186Proteintech groupPD-L1PD-L15%PD-L178.0%PD-L154.3%SCLCPD-L1PD-L1SCLCSCLC PD-L1 NSCLCCheckmate026[17]Nivolumab2017ASCO[18]tumor mutation burden, TMB17 mut/Mb14TMBSCLC995%SCLCTMB[19]SCLC TMB9 mut/Mb90TMB19.6 mut/MbSCLCTMBSCLC195, 777[20]insertions and deletions mutations, IndelPD-1SCLCIndelSCLC PembrolizumabMSI-HdMMR5KEYNOTE-028SCLC MSI-HdMMRCRduration of response, DOR8.9 mo+MSI-HdMMRSCLCSCLCMSI-HdMMRSCLCTCRSCLC NSCLC em P53 /em PD-L1[21]PD-1SCLCP53[22-24]SCLC30%SCLC SCLCSCLC em MYC /em CD47PD-L1[25]MYCCD47PD-L1SCLC6% em MYC /em SCLCPD-1/PD-L1MYCDLL3WEEK1AZD1775PARPSCLCSCLC 3.?SCLC SCLCCD47SIRPCD47[26, 27]SCLCCD47CD47SCLC[28]CD47Hu5F9-G4NCT02216409 [29]NKBMS-986012IgG1NKBMS-986012/CA001-030[30]SCLC18% 4.? NSCLCSCLCSCLCSCLCSCLCSCLC Funding Statement No.2014Z014, No.2015Q049, No.2015Z094, No.2014Z016 This paper was supported by grants from the Scientific Research Funds of Jilin Province of Health and Family Planning Commission (No.2014Z014, No.2015Q049, No.2015Z094, No.2014Z016)(All to Ying CHENG).